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01/01/2009 and 31/01/2013 were identified in The Health Improvement Network 
(THIN) database. Patients were excluded if they had history of; chronic kidney dis-
ease stage 4/5, cancer, neuropathic pain, sciatica/radiculopathy, diabetes, back pain 
or a prior prescription for a study drug. Patients were classified as responders if they 
were either “cured” (discontinued treatment) or stable (remained on treatment), 
or a non-responder if they were referred to a pain clinic or switched to a CYP2D6-
independent analgesic. Multivariate logistic regression was used to identify the pre-
dictors of response and estimate the influence of CYP2D6-inhibitors. Results: The 
cohort consisted of 43,632 patients: 90.8% were responders, and CYP2D6-inhibiting 
drugs were prescribed to 33.8% of the cohort. Almost three times as many patients 
failed to respond in those prescribed a CYP2D6-inhibitor (16% vs. 6%). Controlling 
for medication, demographics and co-morbidities the logistic regression indicated 
the odds of responding for those with a CYP2D6-inhibiting co-prescription were 
39% lower than those without a co-prescription for a CYP2D6 inhibiting drug (OR= 
0.61, 95% CI 0.57 to 0.66). ConClusions: Chronic non-malignant pain patients 
with a co-prescription for a CYP2D6-inhibiting medication were significantly less 
likely to respond to analgesia treatment and therefore received suboptimal pain 
management.
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objeCtives: Transfusional iron overload is common among patients with myelo-
dysplastic syndromes (MDS) receiving red blood cell (RBC) transfusions. Emerging 
evidence indicates that iron chelation therapy (ICT) could improve health outcomes 
in MDS patients with low/intermediate-1 IPSS risk. This study aimed to investigate 
clinical evolution and transfusion dependency of MDS patients under ICT with 
deferasirox, in clinical practice. Methods: This was a retrospective analysis of a 
hospital registry of MDS patients followed-up by imunohemotherapy. Longitudinal 
data records were aggregated in 3 months periods. Exploratory analysis was per-
formed to characterize patients. Generalized Estimation Equation models were 
used to estimate the effect of time on average ferritin levels and RBC transfusions, 
controlled by patient’s initial conditions and deferasirox dose. Generalized Linear 
Mixed-effects Models were estimated to assess individualized evolution patterns. 
In modelling only patients chelated for ≥ 6 months were considered. Results: A 
total of 877 records of 17 MDS patients (53% male), classified as low risk at diagnosis, 
were included in the analysis. Median ages at diagnosis, beginning of RBC transfu-
sions and beginning of ICT were 71, 74 and 77, respectively. Patients had received 
an average of 51.6±26.2 RBC units before ICT. Average values of clinical param-
eters were calculated for each patient. Sample medians were: ferritin 3674.3ng/mL, 
hemoglobin 8.2g/dL, alkaline phosphatase 91.3UI/L, gamma-glutamyl transferase 
0.4UI/L, aspartate aminotransferase 27.0UI/L, alanine aminotransferase 42.9UI/L and 
blood creatinine 0.9mg/dL. From the 8 patients chelated ≥ 6 months: 6 presented 
a decrease on ferritin levels and 4 presented a decrease in RBC transfusions (one 
reaching transfusional independence), over time. Marginal models demonstrated 
that average ferritin levels and number of RBC decrease with time (β = -141.9 p= 0.008; 
β = -0.043 p= 0.001, respectively). ConClusions: Analysis of real-world data from 
a Portuguese registry of transfusion-dependent MDS patients chelated with def-
erasiforx, for ≥ 6month, indicated that both ferritin levels and RBC transfusions 
tend to decrease with time.
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objeCtives: To study the clinical presentations, treatment pattern and outcome of 
patients diagnosed with Guillain-Barre Syndrome (GBS). Methods: A retrospective 
observational study, carried out in a tertiary care teaching hospital. Data of patients 
diagnosed with GBS and admitted to ICUs, medical wards and neurological wards 
from 2008 to 2013, was collected from medical records department (MRD) registry 
using ICD-10 code G61.0 Results: During the study period total 130 patients were 
diagnosed with GBS. The mean age of the study population was 35.3±20.7 years 
(mean±SD) and 55.4% (n= 72) patients were male. Hospital admissions due to GBS 
showed a marked escalation yearly from 2008 to 2013. 48.4% (n= 63) of patients 
reported flu like syndrome along with loose stools one week prior to GBS onset. The 
main clinical manifestations of GBS, bilateral ascending weakness and areflexia 
was seen in 69.2% of patients. Respiratory paralysis is the major cause of mortality 
in GBS patients and was present in 17.7% (n= 23) of the patients. Among the study 
population 49.2% (n= 64) of patients received intravenous Ig (IVIg) therapy and 11.5% 
(n= 15) of patients underwent plasmapheresis. Other supportive therapies included 
were physiotherapy/occupational therapy (13.8%) and corticosteroid therapy (10.8%). 
Due to high economic burden 14.6% (n= 19) of patients denied all treatments. Among 
the patients who received IVIg therapy, 4.7% showed complete recovery and 82.8% 
showed significant improvement whereas patients who received plasmapheresis, 
85.7% showed significant improvement. The mortality rate in patients who received 
IVIg was 1.6% whereas in plasmapheresis was 7.1%. ConClusions: Both IVIg and 
plasmapheresis treatments showed significant improvement within 3 weeks. In 
our study setting, IVIg was the preferred treatment option due to low side effect 
profile and ease of administration however cost of treatment is higher compared 
to plasmapheresis. Plasmapheresis was associated with complications such as BP, 
HR fluctuations.
the 12-month baseline period, 26% of patients experienced 1 PEx, 15% had 2, and 
20% had ≥ 3. Corresponding proportions over a mean of 27 months of follow-up 
were 16%, 12%, and 52%. The mean PEx rate rose from 1.3 to 1.6/patient-year 
from baseline to follow-up. In the follow-up period, proportions of patients with 
at least 1 PEx and rates of PEx were higher among adults (84%; 1.7/patient-year) 
versus adolescents (70%; 1.5/patient-year) and for patients in the severe ppFEV1 
group (86%; 2.0/patient-year) compared with the mild group (70%; 1.1/patient-
year). Among patients with PEx, 61% required inpatient hospitalization (mean ± 
SD length of stay, 13.3 ± 7.4 days) and 73% required either hospitalization or IV 
antibiotics. ConClusions: The majority of patients with CF homozygous for the 
F508del CFTR gene mutation experience at least one PEx annually and many PEx 
are associated with lengthy hospitalizations. The rates of PEx increase over time 
and are highest for adults and for those in the most severe lung function group, 
consistent with a progressive disease.
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objeCtives: MICA antibody identification is a test performed on transplant 
patients to check for the presence of donor-specific MICA for the purpose of pre-
dicting the incidence of organ rejection among transplant patients. The purpose 
of this assessment was to evaluate the effectiveness. Methods: The literature 
search was performed using 8domestic research databases and 3core databases. A 
total of 9papers that remained. Each of the stages from literature search to applica-
tion of selection criteria and data extraction was independently by 2researcher. 
The SIGN was used for the quality assessment. Results: There were 5studies 
reporting on the medical results of kidney transplant patients. 2of the studies 
reported no significant differences in the graft survival rate and incidence of organ 
rejection(p= .67). There were 3studies reporting of heart transplant patients. There 
was one study reporting of lung transplant patients. The incidence of organ rejec-
tion was reported to be 42.0%(p= ns). ConClusions: MICA Identification lacked 
clinical effectiveness for the following reasons: i)there were no significant differ-
ences in the graft survival rate and incidence of organ rejection; ii)it is difficult to 
determine whether the different results for the graft survival rate and incidence 
of organ rejection reported.
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objeCtives: The efficacy and safety of capsaicin 8% patch (Qutenza) for treat-
ing painful diabetic peripheral neuropathy (PDPN) has recently been studied but 
direct comparison with other treatments is lacking. The objective was to obtain 
estimates of the relative efficacy and safety of oral treatments for PDPN and cap-
saicin 8% patch. Methods: A systematic literature review (SLR) and network 
meta-analysis (NMA) were conducted. The SLR collated data from all published 
randomized controlled trials (RCTs) comparing either pregabalin, duloxetine, 
amitryptiline or gabapentin. Efficacy data for capsaicin 8% patch was obtained 
from 12-week placebo-controlled RCT (STEP) and a 12-month open-label ran-
domized study versus standard of care (PACE). Electronic databases (Embase, 
Medline, CRD-Dare and Cochrane) were searched up to February 2014. Search 
results were screened, eligible studies were assessed for risk of bias and data 
were extracted. Efficacy outcomes selected for Bayesian NMA (WinBUGS v.1.4) 
included responder status (≥ 30%/ ≥ 50% reduction in pain) and absolute change 
in pain score from baseline. Safety endpoints included nausea, diarrhoea, som-
nolence and dizziness. Results: Out of the 400 unique records identified, 24 
were eligible for inclusion in the review. Eight studies were included in the NMA 
for ≥ 30% pain reduction, 10 for ≥ 50% pain reduction, and 11 reporting pain score 
change. No significant differences were observed between treatments regard-
ing either responder rate based on ≥ 30%/ ≥ 50% pain reduction or pain score 
change from baseline. Scenario analyses considering different dosing regimens 
of pregabalin and duloxetine, different definitions of clinical endpoints and inclu-
sion of PACE trial data did not significantly change the results. The capsaicin 8% 
patch exhibited none of the investigated safety events, whereas all orals reported 
dose-dependent side-effects. ConClusions: This NMA found that capsaicin 
8% patch, pregabalin, duloxetine, and gabapentin do not have different efficacy 
profiles for PDPN; however, capsaicin 8% patch exhibits fewer systemic adverse 
events.
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objeCtives: To determine the rates of co-prescription of CYP2D6-inhibiting medi-
cations with pain medication and the impact on response rates to pain medications, 
in the UK primary care setting. Methods: Codeine and tramadol are prodrugs 
requiring activation by the CYP2D6 enzyme. These drugs may have limited effective-
ness when co-prescribed with other medications known to inhibit the CYP2D6 path-
way. This contrasts with CYP2D6-independent analgesia, e.g. buprenorphine, which 
do not require CYP2D6 activation. We identified the co-prescription of three study 
pain medications; buprenorphine, codeine and tramadol with CYP2D6-inhibiting 
drugs including amitriptyline and fluoxetine. Patients aged ≥ 18 years with chronic 
non-malignant pain and prescribed buprenorphine, codeine or tramadol between 
